Exicure opened lower at $1.09, compared with its previous close of $1.11. In the last trading session, the stock traded between $0.98 and $1.10. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Exicure is now worth
$ 0.63
Resulting in a loss of
$ 99.37 (99.37%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.05 (-4.50%)
Day High
$1.10
Day Low
$0.98
Day Open
$1.09
Prev Close
$1.11
Volume
15,390
1W Return
8.72%
1M Return
-2.48%
3M Return
-22.57%
6M Return
-68.64%
1Y Return
-71.58%
Fundamentals
Market Cap ($ Mn)
7
PE Ratio
-
PB Ratio
8.43
PEG Ratio
-
ROE
-65.30%
ROCE
-42.75%
EPS (TTM)
$-0.18
Investment Returns
1 Week
8.72%
1 Month
-2.48%
3 Months
-22.57%
6 Months
-68.64%
9 Months
-75.06%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
11Nov
Exicure agrees to sell GPC-100 assets to GPCRT for $4.8M
Exicure sold GPC-100 program assets to GPCRT Inc. for KRW 6.5 billion (approx US$4.8 million). Transaction signed November 4, 2026, transferring IP, clinical data, and license rights. Payment split into tranches: KRW 500 million paid, KRW 2 billion by Nov 16, KRW 4 billion at closing. GPCRT assumes costs incurred after September 1, 2026; Exicure retains prior liabilities.
2 days ago
16Sep
Exicure secures Nasdaq compliance extension through December 2, 2026
Exicure received a Nasdaq compliance extension on September 10, 2026. The deadline to meet the $2.5 million equity requirement is December 2, 2026. Failure to comply could result in delisting of common stock.
1mo ago
3Aug
Exicure issues 172,058 shares to GPCR to settle $1M milestone
Exicure settles a $1.0 million clinical milestone with GPCR Therapeutics via equity issuance, preserving cash liquidity. The transaction involves 172,058 shares valued at $5.81 each, triggered by the Phase 2 trial completion of Burixafor.
3mo ago
30Jun
Exicure expands board to six directors with new appointments
Exicure, Inc. expanded its Board of Directors to six members with the appointment of Jin Young Go and Eui Seok Han as Class III directors, effective June 30, 2026. The Board accepted the resignation of Jung Kyu Ham and confirmed Eui Seok Han meets Nasdaq independence standards. The Audit Committee remains unchanged, while a new Compensation Committee was established.
4mo ago
11Jun
Exicure has until July 20 to fix Nasdaq equity gap
Exicure, Inc. received a notification from Nasdaq on June 5, 2026, regarding non-compliance with Listing Rule 5550(b)(1) due to stockholders' equity falling to approximately $2.1 million, below the required $2.5 million minimum. The company has until July 20, 2026, to submit a plan to regain compliance, potentially receiving a 180-day extension if accepted. Management attributes the equity decline to executive separation expenses and legacy consulting obligations, noting ongoing restructuring efforts.
